Bristol-Myers Squibb
Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in the United States. Founded in 1887, the company has established itself as a pioneer in innovative medicines, particularly in oncology, immunology, and cardiovascular disease.
With a strong operational presence across North America, Europe, and Asia, BMS is renowned for its core products, including the groundbreaking cancer therapies Opdivo and Yervoy, which have transformed treatment paradigms. The company’s commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. Bristol-Myers Squibb continues to shape the future of healthcare with its unique approach to addressing unmet medical needs.
+42 vs industry average
Bristol-Myers Squibb’s score of 80 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Bristol-Myers Squibb?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Bristol-Myers Squibb's reported carbon emissions
Bristol Myers Squibb (BMS), a pharmaceutical preparation manufacturing company headquartered in the US, has reported its carbon emissions for recent years, demonstrating a commitment to reducing its environmental impact.
2024 Emissions: In 2024, BMS reported a total of approximately 2.01 billion kg CO2e. This breakdown includes:
- Scope 1 Emissions: Approximately 206.73 million kg CO2e.
- Scope 2 Emissions (Market-based): Approximately 104.65 million kg CO2e.
- Scope 3 Emissions: Approximately 1.70 billion kg CO2e, with purchased goods and services accounting for the largest portion at about 1.22 billion kg CO2e.
2023 Emissions: For 2023, BMS recorded total emissions of approximately 2.12 billion kg CO2e.
- Scope 1 Emissions: Approximately 208.53 million kg CO2e.
- Scope 2 Emissions (Market-based): Approximately 158.45 million kg CO2e.
- Scope 3 Emissions: Approximately 1.75 billion kg CO2e.
2022 Emissions: In 2022, total emissions were approximately 2.14 billion kg CO2e.
- Scope 1 Emissions: Approximately 212.28 million kg CO2e.
- Scope 2 Emissions (Market-based): Approximately 160.55 million kg CO2e.
- Scope 3 Emissions: Approximately 1.77 billion kg CO2e.
Climate Commitments and Targets: Bristol Myers Squibb has set ambitious targets to achieve net-zero greenhouse gas emissions. Key commitments include:
- Net-Zero by 2050: BMS aims to achieve net-zero emissions across its entire value chain by 2050. This target includes Scope 1, Scope 2, and Scope 3 emissions.
- Scope 1 & 2 Reduction Target: BMS has committed to a near-term reduction of 54.6% in absolute Scope 1 and 2 GHG emissions by 2033, using 2022 as the base year.
- Scope 3 Reduction Target: In line with its near-term Scope 1 & 2 goals, BMS also commits to reducing absolute Scope 3 GHG emissions from fuel and energy-related activities by 54.6% by 2033 from a 2022 base year.
- Supplier Engagement: By 2028, BMS aims to engage 75% of its suppliers, weighted by emissions, to develop science-based targets for purchased goods and services, capital goods, and upstream transportation and distribution.
- Long-Term Scope 1 & 2 Reduction: BMS is working towards a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2050, from a 2022 base year.
- Long-Term Scope 3 Reduction: Similarly, BMS aims for a 90% reduction in absolute Scope 3 GHG emissions by 2050, from a 2022 base year.
- Corporate Fleet: By 2040, the company aims to have 100% electric vehicles in its corporate fleet globally and achieve net-neutral carbon emissions.
These targets align with the Science Based Targets initiative (SBTi) and demonstrate BMS's dedication to contributing to global climate goals.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Bristol-Myers Squibb’s Climate Goals (2030 & 2050)
4 goals2040
by 2040, achieve, globally, 100% electric vehicles in our co…
by 2040, achieve, globally, 100% electric vehicles in our corporate fleet, net neutral carbon emissions.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Bristol-Myers Squibb
Frequently asked questions
Common questions about Bristol-Myers Squibb’s sustainability data and climate commitments
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project